This report compiles and summarizes all published recommendations from CDC's Advisory
Committee on Immunization Practices (ACIP) for use of pneumococcal vaccines in adults …

Pediatric bacterial pneumonia is an important contributor to childhood morbidity and
mortality. A short antibiotic course seems to be sufficient for the outpatient management of …

Objectives To achieve the therapeutic effects, antibiotics must penetrate rapidly into infection
sites and bind to targets. This study reviewed updated knowledge on the ability of antibiotics …

In June 2010, Greece introduced the 13-valent pneumococcal conjugate vaccine (PCV13)
for pediatric vaccination and has since observed a large decrease in pneumococcal disease …

Abstract Background As of June 2023, two pneumococcal conjugate vaccines, 20-(PCV20)
and 15-(PCV15) valent formulations, are recommended for US infants under a 3+ 1 …

This study evaluated the clinical and economic impact of routine pediatric vaccination with
the 15-valent pneumococcal conjugate vaccine (PCV15, V114) compared with the 13-valent …

Streptococcus pneumoniae can co-infect persons who have viral respiratory tract infections.
However, research on S. pneumoniae infections that are temporally associated with SARS …

At its October 2022 meeting, the Advisory Committee on Immunization Practices*(ACIP)
approved the Recommended Child and Adolescent Immunization Schedule for Ages 18 …

Pneumococcal conjugate vaccines (PCVs) prevent nasopharyngeal colonization with
vaccine serotypes of Streptococcus pneumoniae, leading to reduced transmission of …

Abstract Background In 2022–2023, 15-and 20-valent pneumococcal conjugate vaccines
(PCV15/PCV20) were recommended for infants. We aimed to estimate the incidence of …